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Abstract
Comparison of microRNA (miRNA) expression profiles in the noncancerous liver tissues adjacent to hepatocelluar
carcinomas (HCCs) was a strategy to identify postoperative prognostic predictors in this study. Expression profiles of 270
miRNAs were determined in the paraneoplastic liver tissues of 12 HCC patients with known postoperative prognosis. A
panel of candidate miRNA predictors was identified. The prognostic predictive value of these candidate miRNAs was then
verified in 216 postoperative HCC patients. Univariate analysis identified 8 and 3 miRNA predictors for recurrence-free (RFS)
and overall (OS) survivals, respectively. Multivariate analysis revealed high expression levels of miR-155 (HR, 2.002 [1.324–
3.027]; P=.001), miR-15a (HR, 0.478 [0.248–0.920]; P=.027), miR-432 (HR, 1.816 [1.203–2.740]; P=.015), miR-486-3p (HR,
0.543 [0.330–0.893]; P=.016), miR-15b (HR, 1.074 [1.002–1.152]; P=.043) and miR-30b (HR, 1.102 [1.025–1.185]; P=.009)
were significantly associated with RFS. When clinicopathological predictors were included, multivariate analysis revealed
that tumor number and miR-432, miR-486-3p, and miR-30b expression levels remained significant as independent
predictors for RFS. Additionally, expression knockdown of miR-155 in J7 and Mahlavu hepatoma cells resulted in decreased
cell growth and enhanced cell death in xenograft tumors, suggesting an oncogenic effect of miR-155. In conclusion,
significant prognostic miRNA predictors were identified through examination of miRNA expression levels in paraneoplastic
liver tissues. Functional analysis of a miRNA predictor, miR-155, suggested that the prognostic miRNA predictors identified
under this strategy could serve as potential molecular targets for anticancer therapy.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common solid
malignant tumors worldwide and the third leading cause of cancer
related death. Hepatitis viruses infection (hepatitis B or C) and
long-term ingestion of some chemical agents (alcohol or aflatoxin
B1) are the known etiological factors for the occurrence of HCC
[1]. Decisions on the therapeutic modalities are made largely
according to the status of tumor growth at the time of diagnosis as
well as the expected outcomes of the diseases. Several clinical
staging systems have been proposed based on various clinical
variables. In general, high-grade and fast growing tumors tend to
have a poorer prognosis, while low-grade and slow growing
tumors usually associate with a more favorable outcome. For this
reason, postoperative recurrence rate and overall survival (OS) in
HCC patients are usually used as indicators to evaluate the
association between the tissue expression of a molecular factor and
the status of HCC cell growth. Such studies could lead to the
discovery of clinically applicable prognostic markers, which are
pivotal in helping clinicians to improve their decision making in
anti-HCC therapies.
MicroRNAs (miRNAs) are non-coding, single stranded RNAs
of ,22 nucleotides, processed from endogenous precursor RNAs
with stem-loop structures. They negatively regulate gene expres-
sion by targeting mRNAs for cleavage or translational repression
[2], and thus play important roles in crucial biological processes,
such as organ development, cell differentiation and proliferation,
cell apoptosis, and cancer cell invasion [3]. Furthermore, because
of their abilities to exert functions similar to tumor suppressors or
oncogenic proteins, miRNAs are believed to play an important
role in carcinogenesis. To date, distinct expression patterns of
miRNA were found to associate with various clinical features as
well as patient survivals in many cancers [4–8]. Additionally,
miRNA expression profiling was found to be a better method to
classify poorly differentiated tumors, when compared with mRNA
expression profiling [9]. These studies suggested that miRNAs
could potentially be developed into a diagnostic or prognostic
marker.
Identification of miRNAs differentially expressed between
tumors and their non-tumor counterparts is an approach adopted
by most researchers. Such experiments have been conducted in
HCC by a few groups with inconsistent results. Theoretically, the
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be considered as candidate diagnostic markers, but not prognostic
predictors. To identify prognostic predictors, miRNAs differen-
tially expressed in the paraneoplastic liver tissues obtained from
HCC patients with known prognosis were searched. To avoid bias
resulting from different clinical stages of the study patients, we
examined miRNA expression profiles in HCC patients who were
all eligible for surgical resection (Barcelona Clinic Liver Cancer
[BCLC] stage A). In these patients, all cancerous tissues were
surgically removed, resulting in a clinically homogeneous group
with no detectable malignant tumors in the liver. Subsequently,
the expression levels of miRNAs in the liver tissues were correlated
with the time to tumor recurrence. The prognostic predictive value
of the candidate miRNA markers were verified in a larger cohort
of patients (n=216). Finally, functional analysis was performed for
one of the significant miRNA predictors in two highly tumorigenic
hepatoma cell lines to investigate its oncogenic effect.
Materials and Methods
Patients and Tissue Specimens
For identifying prognostic miRNA markers, the adjacent
noncancerous liver tissues (paraneoplastic tissues) from 228 HCC
patients were collected. The noncancerous liver tissues were 1 cm
from the tumor site. The clinical records of 228 HCC patients
receiving total removal of liver tumors from July 1998 to Aug 2004
in Chang Gung Medical Center, Taiwan were retrieved from
Institutional Tissue Bank. Of the 228 patients, 12 with known
better and poorer prognosis were subjected for the first-step (pilot)
study. Six patients had a recurrence-free survival (RFS) time for
more than 5 years (defined as a better prognosis) and six patients
had rapid relapse within six-month after operation (defined as a
poorer prognosis). It is generally believed that if recurrence or
metastasis is not found within five years after the initial treatment
of cancer, a complete remission is achieved. Further relapse of
HCC rarely occurs (a plateau is reached) if the patients have a
recurrence-free survival for more than 5 years. The other 216
HCC patients including 46 females and 170 males were included
for subsequent verification analysis. The basic clinical character-
ization of the 228 patients was listed in Table S1 and S2. The
details of sample classification were described in Methods S1. The
study protocol was approved by the Medical Ethics and Human
Clinical Trial Committee of the Chang Gung Memorial Hospital
(IRB No. 100-4016C). Written informed consent was obtained
from all patients, and the study was approved by the Ethics
Committee of Chang Gung Memorial Hospital.
Reverse Transcription-quantitative Real-time PCR (RT-
qPCR) for miRNA
A stem-loop RT-qPCR method for detection of mature
miRNAs was performed according to a previous report [10].
The details of RT-qPCR condition and the quantification software
used were described in Methods S1.
Data Analysis and Statistical Methods
Two normalization methods were used for data analysis in the
pilot study. In one method, the raw Ct data were converted to 39-
Ct data, which were normalized by the way of global median
normalization as previously described [11]. The DCt method (the
second method) was used to calculated expression level normalized
against the miR-30d, which displayed low coefficient of variation
(CV=0.77) and high abundance (mean Ct=24) in liver tissues in
a pilot profiling of the 270 miRNA expression study. The rationale
to select these 270 miRNAs from a pool of 472 miRNAs was
described in the Methods S1. The miRNA expression level was
calculated as POWER(2, DCt)610
6. For further validation by
analyzing a cohort of 216 HCC patients, the DCt method was
adopted to calculate miRNA expression level. In the pilot study,
identification of miRNA markers with significantly differential
expression levels between patients with better and poorer
prognosis was performed using both Mann-Whitney test and
Cox proportional hazard test. Twenty miRNA markers with the
lowest P values in both tests were included as candidate markers.
Associations between miRNA levels and postoperative prognosis
were calculated using the Kaplan-Meier method and univariate
Cox regression to evaluate the differences of RFS and OS between
patients who had high and low expression of candidate miRNAs.
The multivariate Cox regression was executed to evaluate the joint
effect of confounding factors. The experimental cutoffs were
calculated according to the method of minimum P-value approach
in clinical studies [12]. For each parameter, a series of cutoffs were
generated using the following formula: the smallest value + n/10
(the largest value – the smallest value) (n=1 to 9). The
experimental dichotomous groups were thus separated by a cutoff
at least 1/10 or at most 9/10 of the factor range. This way of
grouping was more readily to be used for making treatment
recommendations in the future. The cutoff leading to the smallest
P value was then selected for subsequent Cox proportional hazard
analysis. All statistical analyses were performed with the help of
SPSS version 15.0 (Chicago, IL).
Cell Lines and Lentiviral Transduction
Human HCC cell lines J7 [13] (obtained from Dr. C. S Yang,
National Taiwan University, Taiwan) and Mahlavu [14] (obtain
from Dr. C. P. Hu, Veterans General Hospital, Taiwan) were
maintained in Dulbecco’s modified Eagle’s medium containing
10% fetal calf serum. The inhibited endogenous miR-155 vector
(pmiRZip-155 lentivector, SBI System Biosciences, Mountain
View, CA) and negative control (pmiRZip lentivector) were
transduced into J7 and Mahlavu cell lines using the lentivector
expression system. The lentiviral packaging plasmids (pPACKH1
Packaging Plasmid) were purchased from SBI. Packaging of
lentiviral expression vector into pseudoviral particles and delivery
of packaged lentivector constructs into target cells were performed
according to the manufacturer’s procedures. Lentiviral titer was
determined by real-time Q-PCR on an ABI 7500 using lentiviral
titer kit (MellGen Laboratories Inc., Surrey, BC, Canada). The
expression levels of pmiRZip-155 lentivirus expressing anti-miR-
155 small RNAs were determined using stem-loop RT-qPCR.
The anti-miR-155 primer sequences used were as follows: RT
primer, 59-CTCAACTGGTGTCGTGGAGTCGGCAATT-
CAGTTGAGTTAATGCT-39; specific (forward) primer, 59-
CGGCGGGACCCCTATCACGATT-39; and the universal re-
verse primer, 59-CTGGTGTCGTGGAGTCGGCAATTC-39.
Assessment of Cell Proliferation and Apoptosis
Cell proliferation was assessed using Thiazolyl Blue Tetrazolium
Bromide (MTT, Sigma, St. Louis, MO) assay described previously
[15]. Cells apoptosis was evaluated by Terminal Uridine Nick-End
Labeling (TUNEL) Assay, where DNA fragmentation was
detected using the DeadEndTM Fluorometric TUNEL System
(Promega, Madison, WI). The experiments were carried out
according to the manufacturer’s procedures.
Immunoblot Analysis
Proteins were loaded on a 10% SDS-polyacrylamide gel for
electrophoresis before being transferred to a PVDF membrane
(PerkinElmer, Boston, MA). The membrane was blotted with
miRNA Predictors in HCC
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37188Figure 1. Association between postoperative survivals and expression levels of prognostic miRNAs. (A) Comparison of postoperative
RFS between patients with higher and lower expression levels of miR-15a, miR-486-3p, miR-381, miR-30c, miR-155, miR-432, miR-15b and miR-30b,
respectively. (B) Comparison of postoperative OS between patients with higher and lower expression levels of miR-29a, miR-486-3p and miR-876-5p.
(C) Combination of six miRNA (miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b) markers as a prognostic score for RFS in HCC. ‘n’
represents the number of samples in each miRNA marker. The P value from the log rank test is shown in each panel.
doi:10.1371/journal.pone.0037188.g001
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Santa Cruz, CA), cyclin D1, Bcl-xL, Bcl-2 (Epitomics Inc,
Burlingame, CA), or GAPDH (Chemicon, Bedford, MA) for
detection. The blots were incubated with horseradish peroxidase
conjugated secondary antibody and developed using an ECL
detection kit (Millipore Corp., Bedford, MA). The intensities of
immunoreactive bands were quantified using Image Gauge
software (Fuji Film, Tokyo, Japan) on a densitometer.
Xenograft Models
Five-week-old, male BALB/cAnN.Cg-Foxnl
nu/CrlNarl nude
mice were divided into two groups for subcutaneous injection
using J7 (1610
6/200 mL PBS) or Mahlavu (1.5610
6/200 mL PBS)
cells. The cells were infected with either the lentivector expressing
antisense miR-155 (n=6 for J7 xenograft; n=5 for Mahlavu
xenograft) or the control lentivector (n=6 for J7 xenograft; n=5
for Mahlavu xenograft). The tumor volume (mm
3) was measured
and calculated using the formula (W
26L)/2 (W, the smallest
diameter; L, the longest diameter). Mice were sacrificed and the
tumors were weighed at day 14 and day 36, respectively, post
subcutaneous injection of J7 and Mahlavu cells. All animal
experiments were performed in accordance with U.S. National
Institutes of Health guidelines, and the Chang Gung Institutional
Animal Care and Use Committee Guide for Care and Use of
Laboratory Animals. This study was conducted under the
approval of Chang Gung Institutionally Animal Care and Use
Committee (IACUC Approval No. CGU09-023).
Immunohistochemistry
Paraffin-fixed xenograft tumor sections (5-mm thick) were
prepared for serial xenograft tumor sections and immunohisto-
chemistry was performed to detect Ki-67 as previously described
[16].
Results
Expression Profiles of miRNA in the Paraneoplastic
Noncancerous Liver Tissues in Patients with known
Better and Poorer Prognosis
As the first step of our study, expression profiles of miRNA in
the noncancerous liver tissues from HCC patients with known
better (n=6) and poorer (n=6) prognosis were analyzed to
identify potential prognostic miRNA markers. Twenty miRNA
markers with the lowest P values in two statistical tests were
included as candidate markers. The P values ranged from.010
to.055 using Mann-Whitney test and from.004 to.454 using Cox
proportional hazard analysis.
Identification of miRNA Associated with Postoperative
Survivals in HCC Patients
In the second step of our study, the adjacent noncancerous liver
tissues from 216 HCC patients were used to verify the prognostic
predictive value of the 20 miRNAs candidates. Univariate and
multivariate analysis was performed to examine the association
between the 20 miRNA expression levels and the RFS and OS,
respectively (Table S3). Univariate analysis revealed that miR-155,
miR-15a, miR-381, miR-432, miR-486-3p, miR-30c, miR-15b
and miR-30b were significantly correlated with RFS (P#.021 for
all). On the other hand, miR-29a, miR-486-3p and miR-876-5p
were associated with OS (P#.046 for all). The effect of these
miRNA predictors on HCC RFS was shown using Kaplan-Meier
survival analysis (Fig. 1A). The high miR-15a, miR-486-3p, and
miR-381 expression significantly predicted a longer RFS (P#.020),
while high miR-30c, miR-155, miR-432, miR-15b, and miR-30b
expression significantly predicted a shorter RFS (P#.016) (Fig. 1A).
In addition, a high expression level of miR-29a, miR-486-3p, and
miR-876-5p significantly predicted a longer OS (P#.041) (Fig. 1B).
These significant predictors obtained from univariate analysis were
included for multivariate Cox proportional analysis. The results
showed that miR-155, miR-15a, miR-432, miR-486-3p, miR-15b
and miR-30b were the significantly remaining predictors related to
RFS (Table S3). When combining these 6 miRNA predictors
(miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-
30b) to examine the predictive value, it was found that 1 (0.5%), 7
(3.2%), 35 (16.2%), 66 (30.6%), 67 (31.0%), 35 (16.2%), and 5
(2.3%) patients had 0, 1, 2, 3, 4, 5 and 6 unfavorable miRNA
factors, respectively. Kaplan-Meier analysis revealed that patients
possessing #3 and .3 unfavorable miRNA factors constituted two
RFS distinguishable subgroups (P,.001, Fig. 1C).
Clinicopathological Factors and miRNA Associated with
Postoperative Survivals in HCC
The Cox proportional hazard model was performed to analyze
whether the miRNA predictors (miR-155, miR-15a, miR-432,
miR-486-3p, miR-15b and miR-30b) were independent factors
when clinicopathological variables were included. Univariate
analysis revealed that microvascular invasion, tumor number
.1, largest tumor diameter .3 cm, ascites, AFP.25 ng/mL,
albumin 4.0 g/dL, prothrombin time .12 seconds, AST
.36 U/L, ALT .25 (U/L), higher miR-155 level, lower miR-
15a level, higher miR-432 level, lower miR-486-3p level, higher
miR-15b level, and higher miR-30b level were significantly
associated with a shorter RFS. When these factors were included,
multivariate analysis showed that tumor number .1, higher miR-
432 level, lower miR-486-3p level, and higher miR-30b level were
the significant remaining factors associated with a shorter RFS
(Table S4).
Expression Levels of the Candidate miRNA Predictors
between Non-tumor and Tumor Liver Tissues
When these candidate miRNA prognosis predictors were
examined, it was found that high expression levels of miR-30c,
miR-155, miR-432, miR-15b, and miR-30b were associated with
shorter RFS in HCC patients (Fig. 1A), suggesting a possible
growth promoting effect in HCCs and thus a candidate anti-HCC
target. To further understand the expression levels of these five
miRNA predictors in liver tumor tissues of HCC patients with
known postoperative prognosis, real-time RT-qPCR was carried
out. As shown in figure 2, the expression levels of these markers in
the non-cancerous parts were significantly higher in HCC patients
with poorer prognosis except for miR-432, in which only
borderline significance was observed (P=.055) (Fig. 2C, to the
right). In particular, the expression levels of miR-30c and miR-155
were also significantly higher in tumor parts in patients with
poorer prognosis (PP) (Mann-Whitney test, P,.05, Figs. 2A and
Figure 2. The expression levels of five miRNAs predict a high risk of tumor recurrence in HCC tumor and adjacent non-tumor liver
tissues. The expression levels of miR-30c (A), miR-155 (B), miR-432 (C), miR-15b (D), and miR-30b (E) in 11 pairs of HCC tumor and non-tumor liver
tissues (to the left). The expression levels of five miRNA in HCC non-tumor liver tissues (BP, n=6; PP, n=6) or tumor liver tissue (BP, n=6; PP, n=5)
with known prognosis (to the right). *, P,.05; **, P,.01 (
a Wilcoxon Signed Ranks Test;
b Mann-Whitney test).
doi:10.1371/journal.pone.0037188.g002
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significantly decreased in the tumor parts compared with that in
the non-tumor parts of patients with better prognosis (BP)
(Wilcoxon rank sum test, P,.05). If the prognosis was not taken
into consideration, miR-155 expression levels were not signifi-
cantly different between non-tumor and tumor parts in these HCC
patients (Fig. 2B, to the left). Among five miRNAs, only miR-15b
(P,.05) was found significantly up-regulated in the cancerous
tissues (Wilcoxon rank sum test, Fig. 2D, to the left). Therefore, if
we only compared the miRNA levels between cancerous and non-
cancerous liver tissues (without considering the prognosis), only
miR-15b could be identified. These data suggested that compar-
ison of the miRNA expression profiles in the noncancerous liver
tissues in HCC patients with known prognosis is a useful strategy
to identify miRNA markers which can not be found when only
non-tumor and tumor liver tissues were compared.
Expression Knockdown of miR-155 Reduced Cell Viability
in Hepatoma Cells
Of the five miRNAs markers, in which high expression levels
were associated with a shorter RFS, only miR-155 displayed
significant difference in the tumor parts compared with that in the
non-tumor parts of patients with better prognosis, and in both the
non-tumor and tumor parts between patients with better and
poorer prognosis respectively (Fig. 2B, to the right), thus this
marker was selected for functional knockdown study. Two highly
tumorigenic hepatoma cell lines, J7 and Mahlavu cells, were
transduced with miRZip-155 lentivirus, a lentivirus expressing
anti-miR-155 small RNAs (for miR-155 expression knockdown),
or empty miRZip (as a mock control). Three days after virus
infection, the culture cells expressed high levels of green
fluorescent protein (GFP), a marker encoded by the miRZip
vector (Fig. 3A). The anti-miR-155 expression levels were
measured using anti-miR-155 primers by stem-loop RT-qPCR
(Fig. S1). Cell proliferation decreased significantly in miR-155
knockdown J7 and Mahlavu cells, when compared with that in
miRZip control cells (Fig. 3B, P,.05). The cell cycle related
molecules CDK2, CDK4, cyclin E, and cyclin D1 were down-
regulated in miR-155 knockdown cells (Fig. 3D). TUNEL assay
revealed strong TUNEL labeling in miR-155 knockdown cells.
The expression levels of anti-apoptotic related molecules Bcl-xL
and Bcl-2 also decreased significantly in miR-155 knockdown cells
(Figs. 3C and 3D).
Expression Knockdown of miR-155 Inhibited Tumor
Growth in Hepatoma Xenograft
To understand the effect of miR-155 on tumorigenicity, J7 or
Mahlavu cells transduced with miRZip or miRZip-155 lentivirus
were injected into nude mice. Palpable tumors were observed in
the J7 miRZip group on day 5, while no tumor was found in J7
miRZip-155 group until after day 7. Similarly, palpable tumors
were observed in the Mahlavu miRZip group on day 6, while in
the Mahlavu miRZip-155 group, tumor was not found until after
day 8. All mice of J7 and Mahlavu xenograft models were
sacrificed on day 14 and day 36, respectively, to examine the final
tumor volume. In addition, the levels of anti-miR-155 expressed in
miRZip-155 xenograft tumors were measured using stem-loop
RT-qPCR (Fig. S2). The growth rate, and the final tumor volume
and weight of the miRZip-155 xenografts were significantly
reduced compared with those of the miRZip group in both the J7
and Mahlavu xenograft models (Figs. 4A and 4B). In the miRZip-
155 xenograft tumors, more and stronger TUNEL labeling was
observed in comparison with that in the miRZip group (Fig. 4C).
The expression levels of Ki-67, Bcl-2, CDK2 and cyclin E were
significantly decreased (Figs. 4D and 4E). The xenograft exper-
iments clearly indicated that knockdown of endogenous miR-155
suppressed tumor growth.
Discussion
Comparison of miRNA expression patterns between HCCs and
the adjacent noncancerous liver tissues is a generally adopted
approach. Previously, expression profiles of miRNA in HCCs have
been investigated by several groups. However, the data derived
from different studies vary greatly. For example, Murakami et al.
analyzed miRNA expression profiles in 24 HCC tissues, 22
adjacent non-tumor tissues, primary cultured hepatocytes and two
control cell lines using the microarray methods [17]. Huang et al.
using a similar approach to analyze 10 pairs of samples from non-
viral hepatitis patients [18]. As a result, completely distinct
miRNA expression profiles were reported between the two studies.
Only miR-195 was mentioned in both studies, but it was over-
expressed in one study and under-expressed in the other.
Subsequently, miRNA profiling was conducted by many groups
to identify aberrantly expressed miRNAs in HCC, while
significant inconsistencies remained [1], [19–25]. In a recent
study, classification of HCC by miRNA profiling was proposed
and miR-517a was identified as an oncogenic miRNA in HCC
[26].
Despite the accumulating yet inconsistent data regarding
aberrant expression of miRNA in HCC, scanty studies were
conducted to illustrate effective prognostic miRNA markers. Some
of the aforementioned studies have demonstrated correlation
between the aberrantly expressed miRNAs and prognosis
[19,21,23,24]. However, the strategy to compare cancerous versus
noncancerous tissues was not initially designed as an attempt to
identify prognostic markers. Thus, inconsistent results could be
expected. In this study, we took a different approach by examining
the miRNA expression levels in patients with different postoper-
ative prognosis. Since postoperative recurrent tumors usually arise
from the remaining noncancerous liver (after surgical resection),
either through de novo oncongenesis or through seeding of micro-
clusters of cancer cells, the cellular compositions of the noncan-
cerous liver thus serve as either a source of de novo cancer
formation or as a suitable tissue environment for cancer cells
seeding and growth. Therefore, it seems reasonable to analyze the
molecular compositions of noncancerous tissues for prognostic
predictors identification. It could be speculated that aberrant
expression of some prognosis related miRNAs in the paraneo-
Figure 3. Reduced cell viability by expression knockdown of miR-155 in hepatoma cells. (A) GFP expression in J7 and Mahlavu cells
transduced with lentivirus carrying miRZip and miRZip-155 vectors, respectively. GFP, an expression marker encoded by the miRZip vector. (B)
Comparisons of the cell proliferation rates assessed by MTT assays between hepatoma cells (J7 [upper panel] and Mahlavu [lower panel]) with
(miRZip-155, red triangles) or without (miRZip, blue squares) expression knockdown. *P,.05; **P,.01. (C) Comparisons of cell apoptosis assessed by
TUNEL assays between hepatoma cells (J7 [upper panels] and Mahlavu [lower panels]) with (miRZip-155) or without (miRZip) expression knockdown.
Cells treated with DNAse I served as a positive control for the TUNEL assay (bottom panel). (D) Immunoblot analysis examined the expression levels of
CDK2, cyclin E, CDK4, cyclin D1, Bcl-xL, and Bcl-2 in lentivirus transduced J7 and Mahlavu cells. GAPDH served as a loading control. Quantitative data
(by densitometer) were shown in the bottom.
doi:10.1371/journal.pone.0037188.g003
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37188Figure 4. Inhibition of tumor growth by miR-155 expression knockdown in subcutaneous hepatoma xenografts. (A and B)
Comparisons of the tumor volumes between hepatoma xenografts with or without miR-155 knockdown. Xenografts were derived from J7 (A) and
Mahlavu (B) cells, respectively. Left panels, the final dissected xenograft tumors. Middle panels, comparisons of the growth curves of xenografts.
Tumor volumes were measured at days 7 to 14 in J7 xenografts and at days 14 to 36 in Mahlavu xenografts after subcutaneous injection of cells.
*P .01; **P .001; Red triangle, with miR-155 knockdown; Solid squares, without miR-155 knockdown. Right panels, comparisons of the mean tumor
weights. Shaded bars, with miR-155 knockdown; Empty bars, without miR-155 knockdown. (C) Comparisons of cell apoptosis assessed by TUNEL
miRNA Predictors in HCC
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early stages of liver cancers. These changes might be masked by
other miRNA alterations at certain stages of cancer development
and thus could no longer be identified by comparing cancerous
and noncancerous tissues thereafter. Actually, in a pilot study, Sato
et al. found that the HCC recurrence-related miRNA signature
was different in the tumor and non-tumor tissues [24]. Most of the
tumor-derived miRNAs were negatively associated with HCC
recurrence, while most of the non-tumor-derived miRNAs were
positively associated with HCC recurrence. Similarly, in our study,
5 of 8 non-tumor-derived miRNAs (62.5%) were positively
associated with recurrence.
After analyzing the expression levels of the 5 miRNAs, in which
a higher level was associated with shorter RFS, only miR-15b
exhibited significant difference between non-tumor and tumor
liver tissues. Actually, in a report by Chung et al. miR-15b was up-
regulation in tumor tissue of HCC patients but the up-regulation
was associated with a better survival [27]. The reason for this
inconsistency was unclear. A possible reason maybe the small
number of samples included. In our study, we showed that higher
expression of miR-15b predicted a high risk of tumor recurrence
through analyzing a larger cohort of HCC patients (n=217). To
clarify the function of miR-15b in HCC, the animal model
experiments should be executed in the future. Base on the previous
and our present results, the strategy used in this study is capable of
identifying new prognostic markers.
During the preparation of this manuscript, aberrant miR-155
expression in HCC was reported in two studies [28,29]. Han et al.
indicated the miR-155 was associated with tumor recurrence and
survival in HCC patients following liver transplantation [28]. The
result was consistent with our findings in clinicopathologic analysis
using non-tumor tissue of HCC patients. In addition, Xie et al.
found the ability of miR-155 in enhancement of liver cell
tumorigenesis, and suggest miR-155 may be a potential target
for HCC therapy [29]. Similarly, in our knockdown miR-155
experiments, the hepatoma cell displayed decrease of cell growth
and enhancement of cell death in vivo as well as in vitro. In fact,
expression knockdown of miR-155 was found to increase cell
apoptosis in malignant lymphoma in a recent study [30].
Most targeted therapies in anticancer treatments adopt a
strategy to utilize an inhibitory molecule to suppress the function
of a growth-promoting target. Therefore, we choose a miRNA of
which over-expression is associated with shorter survival in this
study. Other miRNA predictors which associated with longer RFS
might also serve as targets for HCC treatment. For example,
researchers found restoration of miR-486 expression resulted in
suppression of several pro-oncogenic traits in gastric cancer cell
lines, while inhibition of miR-486 expression caused enhanced cell
proliferation [31]. A recent study reported loss of chromosome
13q, where miR-15a was located, was associated with shortened
cell cycle and increased cell proliferation in dedifferentiated HCC
[32]. In addition, the anti-apoptotic protein Bcl-2 is a target of
miR-15a in chronic lymphocytic leukemia (CLL), where restora-
tion of miR-15a induces apoptosis in MEG-01 cell line, suggesting
a tumor suppressor function of miR-15a [33,34]. In addition, the
OS miRNA predictors (miR-29a, miR-486-3p and miR-876-5p)
might also be developed to become the targets for HCC therapy.
The miR-29a is believed to be a tumor suppressor in both the lung
and pancreatic cancer cell lines and over-expression of miR-29a
suppresses invasion and cell proliferation [35]. Another study
revealed a growth regulatory effect of miR-29 in human gastric
cancer with cell proliferation inhibition and cell cycle arrest [36].
Notably, the identified OS miRNA predictors in this study were all
associated with longer OS. Interestingly, in the literature, most OS
related miRNA markers such as miR-199b [37], let-7g [38], miR-
125b [23], miR-203 [39], miR-199a/b-3p [40], and miR-26 [21]
were positively associated with OS in HCC. Only few miRNAs
(miR-221 and miR-222) were associated with shorter OS [41,42].
In conclusion, through analyzing differential expression of
miRNAs in HCC patients with different postoperative prognosis,
several prognostic miRNA predictors were identified. Among them,
miR-155 functioned as an oncomiR in HCC. The present study
demonstrated that comparison of differential miRNAs expression in
adjacent noncancerous liver tissues is an effective strategy for
identifying prognostic markers. These miRNA predictors served as
potential targets for anticancer therapy in HCC.
Supporting Information
Figure S1 The expression levels of anti-miR-155 RNAs in J7
and Mahlavu cells. By use of stem-loop RT-qPCR, the levels of
anti-miR-155 RNAs were measured in J7 and Mahlavu cells. The
levels of anti-miR-155 RNAs in cells transfected with miRZip
(Empty bar) was assigned as 1. The folds of increase of anti-miR-
155 in cells transfected with miRZip-155 (Shaded bar) were
calculated. Values are mean 6 SD. **, P,.001.
(EPS)
Figure S2 The expression levels of anti-miR-155 RNAs in J7 (A)
and Mahlavu (B) xengraft tumors. By use of stem-loop RT-qPCR,
the levels of anti-miR-155 RNAs were measured in J7 and
Mahlavu xenografts. The levels of anti-miR-155 RNAs in
xenografts transfected with miRZip (Empty bar) was assigned as
1. The folds of increase of anti-miR-155 in xenografts transfected
with miRZip-155 (Shaded bar) were calculated. Values were mean
6 SD. **, P,.001.
(EPS)
Table S1 Basic clinical characterization of 12 patients included
for step-1 screening.
(DOC)
Table S2 Basic clinical characterization of 216 patients included
for verification test.
(DOC)
Table S3 Univariate and multivariate analysis of the expression
levels of 20 candidate miRNA markers for recurrence-free and
overall survivals in HCC patients.
(DOC)
Table S4 Univariate and multivariate analysis of clinicopatho-
logical and miRNA parameters for recurrence-free survival in
HCC patients.
(DOC)
Methods S1
(DOC)
assays between xenografts with (miRZip-155) or without (miRZip) miR-155 knockdown. Upper panels, J7 xenografts; Lower panels, Mahlavu
xenografts. (D) Comparisons of Ki-67 expression assessed by immunohistochemistry between xenografts with (miRZip-155) or without (miRZip) miR-
155 knockdown. Upper panels, J7 xenografts; Lower panels, Mahlavu xenografts. (E) Comparisons of CDK2, cyclin E and Bcl-2 expression levels
assessed by immunoblot between xenografts with or without miR-155 knockdown. GAPDH served as a loading control. C1 and C2, xenografts
without miR-155 knockdown; E1 and E2, xenografts with miR-155 knockdown. Quantitative data (by densitometer) were shown in the right.
doi:10.1371/journal.pone.0037188.g004
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